Home/Pipeline/RejuverSen Antibody

RejuverSen Antibody

Triple-Negative Breast Cancer

Pre-ClinicalIND-enabling, anticipated clinic 2025

Key Facts

Indication
Triple-Negative Breast Cancer
Phase
Pre-Clinical
Status
IND-enabling, anticipated clinic 2025
Company

About Centenara Labs

Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.

View full company profile